DB
UNCY icon

Danske Bank’s Unicycive Therapeutics UNCY Stock Holding History

Danske Bank’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5 Hold
1
– – ﹤0.01% 1092
2026
Q1 		$7 Hold
1
– – ﹤0.01% 1095
2025
Q4 		$6 Hold
1
– – ﹤0.01% 1499
2025
Q3 		$4 Hold
1
– – ﹤0.01% 1448
2025
Q2 		$5 Buy
+1
New +$6 ﹤0.01% 1479

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Danske Bank's UNCY Position: Q2 2026 in Review

Danske Bank held its Unicycive Therapeutics (UNCY) position steady in Q2 2026 at 1 share worth $5. The position accounts for ﹤0.01% of the portfolio, ranked #1092.

Danske Bank first reported a position in UNCY in Q2 2025 and has held it in 5 quarters since. The position peaked at $7 in Q1 2026. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Danske Bank held 1 share of Unicycive Therapeutics worth $5 as of Q2 2026.
  • Danske Bank left its Unicycive Therapeutics share count unchanged in Q2 2026.
  • Unicycive Therapeutics made up ﹤0.01% of Danske Bank's portfolio in Q2 2026, its #1092 holding.
  • Danske Bank first reported a position in Unicycive Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Danske Bank's Unicycive Therapeutics position peaked at $7 in Q1 2026.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.